Developer docs
API playgroundTry for free, no card

Search company profiles

WraSer Pharmaceuticals

Full company profile

uuid000dfn2

Namestring
WraSer Pharmaceuticals
Legal namestring
WraSer Pharmaceuticals
Websiteurl
wraser.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

WraSer Pharmaceuticals is an independent, privately held specialty pharmaceutical marketing and distribution company founded in 2002 and headquartered at 121 Marketridge Road, Ridgeland, Mississippi. The company identifies, develops, and markets proprietary branded prescription products to physicians, pharmacies, and wholesaler distributors across the Southwestern, Southeastern, Mid-West, and Mid-Atlantic regions of the United States.

The company's commercial portfolio consists of five niche branded prescription products across three therapeutic areas: cardiovascular (Zontivity, indicated for reduction of serious cardiovascular events in combination with aspirin/clopidogrel, with a boxed bleeding-risk warning), otic infections (Cetraxal, a preservative-free ciprofloxacin otic solution 0.2%; and Otovel, a ciprofloxacin/fluocinolone acetonide combination for acute otitis media with tympanostomy tubes in children six months and older), and pain management (Trezix, a CIII semi-synthetic opioid carrying extensive boxed warnings; and Nalfon, an NSAID/fenoprofen). These products are supported by dedicated product websites, prescribing information, and digital copay coupon programs for the otic franchise.

WraSer operates a sales-led go-to-market model with three primary channels: direct physician sales, retail/specialty pharmacy distribution, and wholesaler distribution in its four operating U.S. regions. The company is privately held with no disclosed parent company, institutional investors, or funding rounds; leadership includes President Heath Wray and CFO Ken Martin. Revenue, headcount trend, ownership structure, and financial performance are not publicly disclosed.

Short descriptiontext

WraSer Pharmaceuticals is a privately held specialty pharmaceutical marketing and distribution company that sells five niche branded prescription products in cardiovascular, otic, and pain management to physicians, pharmacies, and wholesalers across four U.S. regions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRidgeland, United States
HQ citystring
Ridgeland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
branded pharmaceuticals, specialty prescription drugs, cardiovascular medications, pain management drugs, otic treatments
Industry2 codes
PRIMARYHLAIAJAC
OTC & Consumer Health Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIABAF
Ophthalmic & Otic Generics
NAICS code1 code
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Branded Prescription Pharmaceutical Products
TypeOne Time License
Description

Revenue generated through the sale of proprietary branded prescription pharmaceutical products including cardiovascular medications (Zontivity), pain management drugs (Trezix, Nalfon), and otic treatments (Cetraxal, Otovel). Products are marketed and distributed to physicians, pharmacies, and wholesaler distributors across specific U.S. regions.

wraser.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Marketing or Sales, Personnel, Operations, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

WraSer Pharmaceuticals is an independent specialty pharmaceutical company that identifies, develops, and markets proprietary branded prescription products to physicians, pharmacies, and wholesaler distributors in the Southwestern, Southeastern, Mid-West, and Mid-Atlantic regions of the United States. Its portfolio consists of five niche branded prescription products spanning three therapeutic areas: cardiovascular (Zontivity), otic infections (Cetraxal, Otovel), and pain management (Trezix, Nalfon).

Differentiator
Functional benefit
Problem solved
Product overview1 text field

WraSer Pharmaceuticals is an independent specialty pharmaceutical marketing and distribution company offering a portfolio of five niche branded prescription products. The company focuses on three therapeutic areas: cardiovascular (Zontivity), OTIC/ear infections (Cetraxal, Otovel), and pain management (Trezix, Nalfon). These products are distributed to physicians, pharmacies, and wholesaler distributors across the Southwestern, Southeastern, Mid-West, and Mid-Atlantic regions of the United States.

Product and service5 records
1Zontivity
CategoryCardiovascular prescription pharmaceutical
Description

Zontivity is a branded prescription antiplatelet medication used with aspirin, clopidogrel (Plavix), or both to reduce the risk of serious cardiovascular events such as heart attack, stroke, or death in appropriate patients; it carries a boxed warning for bleeding risk and is prescribed by physicians.

2Trezix
CategoryPain management prescription pharmaceutical
Description

Trezix is a CIII semi-synthetic opioid (dihydrocodeine/acetaminophen/caffeine) branded prescription product used for moderate to moderately severe pain relief when non-opioid alternatives are inadequate; it carries multiple FDA boxed warnings including addiction, abuse, misuse, life-threatening respiratory depression, hepatotoxicity, and neonatal opioid withdrawal syndrome.

3Nalfon
CategoryPain management prescription pharmaceutical
Description

Nalfon (fenoprofen calcium) is a branded prescription NSAID used to relieve mild to moderate pain and to reduce pain, swelling, and joint stiffness associated with arthritis; it is prescribed by physicians for patients requiring non-opioid anti-inflammatory therapy.

4Cetraxal
CategoryOtic prescription pharmaceutical
Description

Cetraxal (ciprofloxacin otic solution) 0.2% is a branded prescription sterile, preservative-free otic antimicrobial solution packaged in single-use 0.25 mL containers delivering 0.5 mg of ciprofloxacin, indicated for otic use in patients with ear infections.

5Otovel
CategoryOtic prescription pharmaceutical
Description

Otovel (ciprofloxacin and fluocinolone acetonide) is a branded prescription otic combination product used in children 6 months of age and older with tympanostomy tubes to prevent excess middle-ear fluid and to treat acute otitis media with tympanostomy tubes (AOMT) caused by susceptible bacteria.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US specialty pharmaceutical company that markets branded prescription products across multiple therapeutic areas through physician and pharmacy channels — directly comparable independent specialty pharma commercial model.

TypeDirect peer
Description

Specialty pharma company focused on branded prescription products distributed to physicians and pharmacies in defined US therapeutic niches — highly comparable GTM and product-portfolio approach to WraSer.

3Assertio Therapeutics
TypeDirect peer
Description

Specialty pharmaceutical company marketing branded pain and neurology prescription products to physicians and pharmacies — directly comparable therapeutic focus and specialty distribution model.

TypeDirect peer
Description

Specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription products — comparable scale, product breadth, and physician/pharmacy distribution strategy.

5Endo International
TypeBroad incumbent
Description

Larger established specialty pharmaceutical company with significant pain management and specialty branded Rx franchises — directly overlapping Trezix/Nalfon therapeutic categories at greater scale.

TypeBroad incumbent
Description

Established specialty pharma focused on CNS and branded prescription products marketed through physician channels — broader portfolio but comparable niche-branded commercial model.

TypeBroad incumbent
Description

Larger specialty pharmaceutical company with branded prescription products in pain, autoimmune, and specialty therapeutic areas — overlapping therapeutic focus at significantly greater commercial scale.

TypeEmerging player
Description

Specialty pharmaceutical company with a mix of branded and generic prescription products sold through US physician and pharmacy channels — similar therapeutic breadth and specialty distribution model.

TypeBroad incumbent
Description

Large diversified pharmaceutical company with specialty branded prescription franchises including cardiovascular and pain products — broad incumbent with overlap on WraSer's Zontivity/Trezix positioning.

TypeEmerging player
Description

Smaller specialty pharmaceutical company historically focused on pain management and CNS prescription products marketed to physicians — comparable therapeutic emphasis and specialty commercial footprint.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

WraSer Pharmaceuticals

Specialty Pharmaceuticalswraser.com

WraSer Pharmaceuticals is a privately held specialty pharmaceutical marketing and distribution company that sells five niche branded prescription products in cardiovascular, otic, and pain management to physicians, pharmacies, and wholesalers across four U.S. regions.

What WraSer Pharmaceuticals does

WraSer Pharmaceuticals is an independent, privately held specialty pharmaceutical marketing and distribution company founded in 2002 and headquartered at 121 Marketridge Road, Ridgeland, Mississippi. The company identifies, develops, and markets proprietary branded prescription products to physicians, pharmacies, and wholesaler distributors across the Southwestern, Southeastern, Mid-West, and Mid-Atlantic regions of the United States.

The company's commercial portfolio consists of five niche branded prescription products across three therapeutic areas: cardiovascular (Zontivity, indicated for reduction of serious cardiovascular events in combination with aspirin/clopidogrel, with a boxed bleeding-risk warning), otic infections (Cetraxal, a preservative-free ciprofloxacin otic solution 0.2%; and Otovel, a ciprofloxacin/fluocinolone acetonide combination for acute otitis media with tympanostomy tubes in children six months and older), and pain management (Trezix, a CIII semi-synthetic opioid carrying extensive boxed warnings; and Nalfon, an NSAID/fenoprofen). These products are supported by dedicated product websites, prescribing information, and digital copay coupon programs for the otic franchise.

WraSer operates a sales-led go-to-market model with three primary channels: direct physician sales, retail/specialty pharmacy distribution, and wholesaler distribution in its four operating U.S. regions. The company is privately held with no disclosed parent company, institutional investors, or funding rounds; leadership includes President Heath Wray and CFO Ken Martin. Revenue, headcount trend, ownership structure, and financial performance are not publicly disclosed.

WraSer Pharmaceuticals firmographics

Firmographics
Name
WraSer Pharmaceuticals
Legal name
WraSer Pharmaceuticals
Website
https://wraser.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Short description
WraSer Pharmaceuticals is a privately held specialty pharmaceutical marketing and distribution company that sells five niche branded prescription products in cardiovascular, otic, and pain management to physicians, pharmacies, and wholesalers across four U.S. regions.
Ownership category
akta.pro rank

WraSer Pharmaceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAJAC
OTC & Consumer Health Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIABAF
Ophthalmic & Otic Generics

Keywords

  • Branded pharmaceuticals
  • Specialty prescription drugs
  • Cardiovascular medications
  • Pain management drugs
  • Otic treatments

Where WraSer Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Ridgeland
HQ country
United States
HQ region
North America

Offices1 record

Markets served

WraSer Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Marketing or Sales, Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

  1. Branded Prescription Pharmaceutical Products: Revenue generated through the sale of proprietary branded prescription pharmaceutical products including cardiovascular medications (Zontivity), pain management drugs (Trezix, Nalfon), and otic treatments (Cetraxal, Otovel). Products are marketed and distributed to physicians, pharmacies, and wholesaler distributors across specific U.S. regions.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

WraSer Pharmaceuticals product offering

Product offering

Core offering

WraSer Pharmaceuticals is an independent specialty pharmaceutical company that identifies, develops, and markets proprietary branded prescription products to physicians, pharmacies, and wholesaler distributors in the Southwestern, Southeastern, Mid-West, and Mid-Atlantic regions of the United States. Its portfolio consists of five niche branded prescription products spanning three therapeutic areas: cardiovascular (Zontivity), otic infections (Cetraxal, Otovel), and pain management (Trezix, Nalfon).

Product overview

WraSer Pharmaceuticals is an independent specialty pharmaceutical marketing and distribution company offering a portfolio of five niche branded prescription products. The company focuses on three therapeutic areas: cardiovascular (Zontivity), OTIC/ear infections (Cetraxal, Otovel), and pain management (Trezix, Nalfon). These products are distributed to physicians, pharmacies, and wholesaler distributors across the Southwestern, Southeastern, Mid-West, and Mid-Atlantic regions of the United States.

Differentiator

Problem solved

Functional benefit

Products and services

  • Zontivity Zontivity is a branded prescription antiplatelet medication used with aspirin, clopidogrel (Plavix), or both to reduce the risk of serious cardiovascular events such as heart attack, stroke, or death in appropriate patients; it carries a boxed warning for bleeding risk and is prescribed by physicians.
  • Trezix Trezix is a CIII semi-synthetic opioid (dihydrocodeine/acetaminophen/caffeine) branded prescription product used for moderate to moderately severe pain relief when non-opioid alternatives are inadequate; it carries multiple FDA boxed warnings including addiction, abuse, misuse, life-threatening respiratory depression, hepatotoxicity, and neonatal opioid withdrawal syndrome.
  • Nalfon Nalfon (fenoprofen calcium) is a branded prescription NSAID used to relieve mild to moderate pain and to reduce pain, swelling, and joint stiffness associated with arthritis; it is prescribed by physicians for patients requiring non-opioid anti-inflammatory therapy.
  • Cetraxal Cetraxal (ciprofloxacin otic solution) 0.2% is a branded prescription sterile, preservative-free otic antimicrobial solution packaged in single-use 0.25 mL containers delivering 0.5 mg of ciprofloxacin, indicated for otic use in patients with ear infections.
  • Otovel Otovel (ciprofloxacin and fluocinolone acetonide) is a branded prescription otic combination product used in children 6 months of age and older with tympanostomy tubes to prevent excess middle-ear fluid and to treat acute otitis media with tympanostomy tubes (AOMT) caused by susceptible bacteria.

Companies that use WraSer Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles2 records

WraSer Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

WraSer Pharmaceuticals partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights5 records

WraSer Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Arbor Pharmaceuticals: US specialty pharmaceutical company that markets branded prescription products across multiple therapeutic areas through physician and pharmacy channels — directly comparable independent specialty pharma commercial model.
  • Vertical Pharmaceuticals (Tris Pharma affiliate): Specialty pharma company focused on branded prescription products distributed to physicians and pharmacies in defined US therapeutic niches — highly comparable GTM and product-portfolio approach to WraSer.
  • Assertio Therapeutics: Specialty pharmaceutical company marketing branded pain and neurology prescription products to physicians and pharmacies — directly comparable therapeutic focus and specialty distribution model.
  • ANI Pharmaceuticals: Specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription products — comparable scale, product breadth, and physician/pharmacy distribution strategy.

Broad incumbents

  • Endo International: Larger established specialty pharmaceutical company with significant pain management and specialty branded Rx franchises — directly overlapping Trezix/Nalfon therapeutic categories at greater scale.
  • Supernus Pharmaceuticals: Established specialty pharma focused on CNS and branded prescription products marketed through physician channels — broader portfolio but comparable niche-branded commercial model.
  • Mallinckrodt Pharmaceuticals: Larger specialty pharmaceutical company with branded prescription products in pain, autoimmune, and specialty therapeutic areas — overlapping therapeutic focus at significantly greater commercial scale.
  • Bausch Health (Valeant): Large diversified pharmaceutical company with specialty branded prescription franchises including cardiovascular and pain products — broad incumbent with overlap on WraSer's Zontivity/Trezix positioning.

Emerging players

  • Mayne Pharma: Specialty pharmaceutical company with a mix of branded and generic prescription products sold through US physician and pharmacy channels — similar therapeutic breadth and specialty distribution model.
  • Pernix Therapeutics: Smaller specialty pharmaceutical company historically focused on pain management and CNS prescription products marketed to physicians — comparable therapeutic emphasis and specialty commercial footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

WraSer Pharmaceuticals social profiles

Digital presence

WraSer Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

WraSer Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles2 records

WraSer Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

WraSer Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WraSer Pharmaceuticals

What does WraSer Pharmaceuticals do?

WraSer Pharmaceuticals is an independent specialty pharmaceutical company that identifies, develops, and markets proprietary branded prescription products to physicians, pharmacies, and wholesaler distributors in the Southwestern, Southeastern, Mid-West, and Mid-Atlantic regions of the United States. Its portfolio consists of five niche branded prescription products spanning three therapeutic areas: cardiovascular (Zontivity), otic infections (Cetraxal, Otovel), and pain management (Trezix, Nalfon).

Is WraSer Pharmaceuticals a public or private company?

WraSer Pharmaceuticals is a private company. It is classified as unknown and is currently operating.

When was WraSer Pharmaceuticals founded?

WraSer Pharmaceuticals was founded in 2002. It employs 11 to 50 people.

Where is WraSer Pharmaceuticals based?

WraSer Pharmaceuticals is headquartered in Ridgeland, United States, in the North America region.

How does WraSer Pharmaceuticals make money?

One revenue line is on record: branded Prescription Pharmaceutical Products.

Who are WraSer Pharmaceuticals's main competitors?

Direct peers on record are Arbor Pharmaceuticals, Vertical Pharmaceuticals (Tris Pharma affiliate), Assertio Therapeutics and ANI Pharmaceuticals. Broad incumbents are Endo International, Supernus Pharmaceuticals, Mallinckrodt Pharmaceuticals and Bausch Health (Valeant). Emerging players are Mayne Pharma and Pernix Therapeutics.

Does WraSer Pharmaceuticals have an API?

No public API is recorded for WraSer Pharmaceuticals.

What industry is WraSer Pharmaceuticals in?

WraSer Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAJAC, OTC & Consumer Health Distributors, with a secondary code of HLAIABAF, Ophthalmic & Otic Generics. Its NAICS code is 424210 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals